Insider Buying: Septerna, Inc. (NASDAQ:SEPN) CFO Purchases 3,718 Shares of Stock

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie purchased 3,718 shares of the stock in a transaction dated Thursday, February 27th. The shares were purchased at an average cost of $5.85 per share, for a total transaction of $21,750.30. Following the transaction, the chief financial officer now owns 40,000 shares in the company, valued at approximately $234,000. The trade was a 10.25 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Septerna Stock Up 1.8 %

NASDAQ SEPN traded up $0.10 on Thursday, reaching $5.80. The stock had a trading volume of 265,272 shares, compared to its average volume of 571,590. The company’s fifty day moving average price is $16.78. Septerna, Inc. has a 12-month low of $4.17 and a 12-month high of $28.99.

Institutional Investors Weigh In On Septerna

Institutional investors and hedge funds have recently modified their holdings of the company. RA Capital Management L.P. purchased a new position in Septerna during the 4th quarter valued at about $160,205,000. TRV GP V LLC acquired a new position in shares of Septerna in the fourth quarter valued at approximately $142,337,000. TRV GP VI LLC acquired a new position in shares of Septerna in the fourth quarter valued at approximately $72,191,000. Samsara BioCapital LLC purchased a new stake in Septerna during the 4th quarter worth approximately $63,399,000. Finally, Driehaus Capital Management LLC acquired a new stake in Septerna during the 4th quarter worth approximately $59,301,000.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on SEPN. Wells Fargo & Company downgraded shares of Septerna from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $43.00 to $14.00 in a report on Tuesday, February 18th. TD Cowen assumed coverage on Septerna in a research report on Tuesday, November 19th. They issued a “buy” rating for the company. JPMorgan Chase & Co. started coverage on Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 target price on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $50.00 price target on shares of Septerna in a report on Tuesday, February 11th.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.